Sinopia Biosciences Secures NIH Grant to Advance AI-Powered Drug Discovery Platform
核心洞察
Sinopia Biosciences (搜索) received a research grant from the National Institute of General Medical Sciences (NIGMS) to advance its proprietary LEADS® (搜索) drug discovery platform.
The grant will support development of novel deep learning algorithms to expand metabolomic characterization of small-molecule libraries while reducing experimental burden.
LEADS® (搜索) platform has already demonstrated success with the identification of novel targets for multiple indications and advancement of a development candidate for Parkinson's disease (搜索).
Sinopia Biosciences (搜索) has been awarded a research grant from the National Institute of General Medical Sciences (NIGMS), part of the National Institutes of Health (NIH), to further advance its proprietary LEADS® (搜索) drug discovery platform. The San Diego-based biotechnology company announced the funding under Award Number R43GM157800, which will support the next phase of platform development focused on data-driven drug discovery capabilities.
Platform Technology and Innovation
The LEADS® (搜索) (LEarn And DiScover) platform represents a significant advancement in drug discovery methodology, combining high-throughput omics data, artificial intelligence/machine learning, and network analyses. The platform leverages system-level readouts to enable unbiased discovery while providing deep mechanistic insight into cellular systems.
Omics technologies enable comprehensive characterization of cellular systems, meaning phenotypes are no longer defined by a few markers, but by hundreds of thousands of cellular features. Sinopia has generated the largest metabolomics dataset characterizing a small-molecule library to date, establishing a foundation for the platform's capabilities.
Grant Objectives and Development Goals
The NIGMS grant will support development of an integrated workflow of computation and experimentation to efficiently expand metabolomic characterization of small-molecule libraries. Phase I of the program will focus on developing novel deep learning algorithms designed to dramatically expand the coverage of chemical and biological space while reducing experimental burden.
The ultimate goal is to develop optimal experimental screening strategies to efficiently scale across significantly larger numbers of compounds, cell lines and systems. This approach aims to address current limitations in drug discovery by enabling more comprehensive and efficient screening processes.
Clinical Validation and Pipeline Progress
LEADS® (搜索) has already demonstrated real-world drug discovery success, including the identification of novel targets for multiple indications and advancement of a development candidate for Parkinson's disease (搜索). The platform's validation through these concrete achievements provides evidence of its potential to transform treatment approaches for complex diseases.
"We are grateful to NIGMS for their support," said Aarash Bordbar, Ph.D., co-founder and Chief Technology Officer of Sinopia Biosciences (搜索). "This non-dilutive funding enables continued development of the LEADS® (搜索) platform as we continue to advance our internal programs and pursue our mission to transform treatment of complex diseases."
Company Background and Strategic Focus
Sinopia Biosciences (搜索) is a privately held biotechnology company headquartered at JLABS San Diego. The company is actively pursuing multiple first-in-class programs with high unmet need, including its lead program for Parkinson's disease (搜索). The company's approach focuses on advancing novel therapeutics identified using its proprietary drug discovery platform.
The research supported by this grant represents the company's commitment to developing innovative approaches to drug discovery that could potentially address significant unmet medical needs across multiple therapeutic areas.